![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
E Romeo, J Auta, AP Kozikowski, D Ma, V Papadopoulos, G Puia, E Costa and A Guidotti
Fidia-Georgetown Institute for the Neurosciences, Washington, DC.
The 2 aryl-3-indoleacetamides (FGIN-1) are a new class of compounds that potently (nM) and selectively bind to glial mitochondrial diazepam binding inhibitor (DBI) receptors (MDR), previously called peripheral benzodiazepine receptors, and increase mitochondrial steroidogenesis. The high-affinity binding of FGIN-1 to MDR derivatives depends on the following chemical characteristics: 1) the dialkylation of the amide; 2) the chain length of this alkyl substitution; and 3) the halogenation of aryl groups appended to the indole nucleus. FGIN-1 derivatives do not bind to gamma-aminobutyric acid (GABAA), GABAB, glycine, glutamate, dopamine, serotonin, opiate, cholecystokinin, beta adrenergic, cannabinoid or sigma receptors. FGIN-1-27 [N, N-di-n-hexyl 2-(4- fluorophenyl)indole-3-acetamide] enters the brain, and for this reason, this FGIN-1 compound is potent and efficacious behaviorally. Like the neurosteroid 3 alpha-5 alpha tetrahydrodeoxycorticosterone (THDOC), FGIN-1-27 delays the onset of isoniazid-induced convulsions, but fails to delay the onset of bicuculline-induced convulsions. However, differently from THDOC, the FGIN-1-27 anticonvulsant action is blocked by the isoquinoline carboxamide PK 11195. In the elevated plus maze test, FGIN-1-27 inhibits neophobia manner that is antagonized by PK 11195 but not by flumazenil. Because FGIN-1-27 binds to MDR and does not bind to the GABAA receptors, it is inferred that FGIN-1-27 may act on GABAA receptors indirectly, presumably via a stimulation of neurosteroid synthesis and release from glial cells.
This article has been cited by other articles:
|
|
 |
|
  M. Gazouli, Z. Han, and V. Papadopoulos Identification of a Peptide Antagonist to the Peripheral-Type Benzodiazepine Receptor That Inhibits Hormone-Stimulated Leydig Cell Steroid Formation J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 627 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Szewczyk and L. Wojtczak Mitochondria as a Pharmacological Target Pharmacol. Rev., March 1, 2002; 54(1): 101 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Berson, V. Descatoire, A. Sutton, D. Fau, B. Maulny, N. Vadrot, G. Feldmann, B. Berthon, T. Tordjmann, and D. Pessayre Toxicity of Alpidem, a Peripheral Benzodiazepine Receptor Ligand, but Not Zolpidem, in Rat Hepatocytes: Role of Mitochondrial Permeability Transition and Metabolic Activation J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 793 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gavish, I. Bachman, R. Shoukrun, Y. Katz, L. Veenman, G. Weisinger, and A. Weizman Enigma of the Peripheral Benzodiazepine Receptor Pharmacol. Rev., December 1, 1999; 51(4): 629 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Pastorino, G. Simbula, K. Yamamoto, P. A. Glascott Jr., R. J. Rothman, and J. L. Farber The Cytotoxicity of Tumor Necrosis Factor Depends on Induction of the Mitochondrial Permeability Transition J. Biol. Chem., November 22, 1996; 271(47): 29792 - 29798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Whalin and K. E. Krueger Identification and Purification of a 10-Kilodalton Protein Associated with Mitochondrial Benzodiazepine Receptors J. Biol. Chem., September 1, 1995; 270(35): 20285 - 20291. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
